# Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma

> **NCT00944801** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of Regensburg** · enrollment: 63 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** Pegylated Liposomal Doxorubicine

## Key facts

- **NCT ID:** NCT00944801
- **Lead sponsor:** University of Regensburg
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-07
- **Primary completion:** 2009-05
- **Final completion:** 2009-05
- **Target enrollment:** 63 (ACTUAL)
- **Last updated:** 2009-07-23

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00944801

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00944801, "Pegylated Liposomal Doxorubicine and Prolonged Temozolomide in Addition to Radiotherapy in Newly Diagnosed Glioblastoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00944801. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*